Kiora Pharmaceuticals Inc (KPRX) USD0.01
Sell:$2.81Buy:$2.88
$0.04
(1.40%)
- This stock can be held in a
Stocks and Shares ISA$0.04
(1.40%)$0.04
(1.40%)Company Information
About this company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Key people
Key facts
- EPICKPRX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS49721T5074
- Market cap$8.67m
- Employees12
- Shares in issue3.04m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.